On September 22, 2022 Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, reported that James Oliviero, President and Chief Executive Officer, will participate in two upcoming investor conferences (Press release, Checkpoint Therapeutics, SEP 22, 2022, View Source [SID1234621365]). Details are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cantor Fitzgerald’s Oncology, Hematology & HemeOnc Conference:

Ladenburg Thalmann Healthcare Conference:

Mr. Oliviero will be presenting at the Ladenburg Thalmann Healthcare Conference. A webcast of the presentation will be available on the News & Events page, located within the Investors section of Checkpoint’s website, View Source, for approximately 30 days after the meeting. Checkpoint will also participate in one-on-one meetings during the conference.